Monte Rosa: A Risky Contrarian Buy As Market Abandons Bull Thesis
· seekingalpha.com
Monte Rosa Therapeutics is rated a risky Buy, as $580 million cash leaves its pipeline worth about $215 million, with MRT-6160 and MRT-2359 catalysts.
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...